疫病|最新！中国RA治疗或将进入精准时代( 二 ) |治疗|中国|

【疫病|最新！中国RA治疗或将进入精准时代】结合对于该类抗体与ABA治疗关系的基础与临床研究结果，我们可以清晰地看到通过抗体状态为患者选择更适合治疗方案是一条值得关注与探索的道路，而相关研究结果的不断积累也为针对性用药选择提供了有价值的循证医学证据。
以往临床中很少提及ACPA的原因在于缺乏有效针对ACPA的药物，阿巴西普注射液是获准在中国销售的第一个也是唯一的CTLA4-Fc融合蛋白，也是世界上自身免疫治疗领域第一个也是唯一的选择性T细胞共刺激调节剂，他的出现将有效的填补此方面空白，从而进一步引领RA治疗进入精准治疗时代。
Sokolove J, Schiff M, Fleischmann R, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous ABAtacept or adalimumab: 2-year results from the AMPLE trial. Annals of the Rheumatic Diseases, 2016, 75:709-714.
Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Annals of the rheumatic diseases, 2014,73:86-94
Rigby W, Buckner J, Bridges, Jr. SL, et alTHU0160?THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICAL EFFICACY AND SAFETY OF ABATACEPT IN SEROPOSITIVE, BIOLOGIC-NA?VE PATIENTS WITH EARLY, MODERATE-TO-SEVERE RA TREATED WITH ABATACEPT OR ADALIMUMAB: DATA FROM THE OPEN-LABEL SWITCH PERIOD OF THE HEAD-TO-HEAD SINGLE-BLINDED ’EARLY AMPLE’ TRIALAnnals of the Rheumatic Diseases 202079:295.